PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 11,984 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $94.12, for a total transaction of $1,127,934.08.
NYSE:PKI opened at $94.12 on Friday. The company has a quick ratio of 0.97, a current ratio of 1.30 and a debt-to-equity ratio of 0.70. PerkinElmer, Inc. has a twelve month low of $71.83 and a twelve month high of $103.00. The company has a fifty day moving average of $88.74 and a 200-day moving average of $88.18. The firm has a market capitalization of $10.46 billion, a P/E ratio of 26.07, a P/E/G ratio of 1.69 and a beta of 1.30.
PerkinElmer (NYSE:PKI) last issued its earnings results on Wednesday, October 30th. The medical research company reported $1.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.01 by $0.05. The business had revenue of $706.92 million for the quarter, compared to analyst estimates of $722.69 million. PerkinElmer had a net margin of 8.27% and a return on equity of 16.45%. PerkinElmer’s revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.90 earnings per share. On average, analysts anticipate that PerkinElmer, Inc. will post 4.08 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Stockholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, January 16th. This represents a $0.28 annualized dividend and a dividend yield of 0.30%. PerkinElmer’s dividend payout ratio is currently 7.76%.
Several hedge funds have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC grew its stake in shares of PerkinElmer by 16.4% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 950 shares of the medical research company’s stock worth $80,000 after acquiring an additional 134 shares during the period. Securian Asset Management Inc lifted its stake in PerkinElmer by 1.2% in the 2nd quarter. Securian Asset Management Inc now owns 11,504 shares of the medical research company’s stock worth $1,108,000 after purchasing an additional 141 shares in the last quarter. Glen Harbor Capital Management LLC lifted its stake in PerkinElmer by 3.9% in the 2nd quarter. Glen Harbor Capital Management LLC now owns 3,840 shares of the medical research company’s stock worth $370,000 after purchasing an additional 144 shares in the last quarter. Simmons Bank boosted its holdings in PerkinElmer by 3.6% in the 2nd quarter. Simmons Bank now owns 4,370 shares of the medical research company’s stock valued at $421,000 after purchasing an additional 150 shares during the period. Finally, Berman Capital Advisors LLC boosted its holdings in PerkinElmer by 4.4% in the 2nd quarter. Berman Capital Advisors LLC now owns 3,641 shares of the medical research company’s stock valued at $350,000 after purchasing an additional 155 shares during the period. 95.93% of the stock is currently owned by institutional investors.
PKI has been the topic of a number of recent analyst reports. Stifel Nicolaus reaffirmed a “buy” rating on shares of PerkinElmer in a research note on Thursday, November 21st. Needham & Company LLC restated a “hold” rating on shares of PerkinElmer in a report on Thursday, October 31st. Raymond James restated an “average” rating and issued a $51.00 price target on shares of PerkinElmer in a research report on Tuesday, November 5th. Bank of America raised shares of PerkinElmer from a “neutral” rating to a “buy” rating and set a $105.00 price objective on the stock in a research note on Thursday, September 26th. Finally, Piper Jaffray Companies lowered shares of PerkinElmer from an “overweight” rating to a “neutral” rating and reduced their price objective for the company from $104.00 to $89.00 in a research note on Thursday, October 31st. Ten equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $76.61.
PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.